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Human JC virus (JCV) is glial cell-specific for growth and expression. This specificity is attributed to the cis-acting
sequences of the two 98-bp tandem repeats in the JCV regulatory region. JCV causes brain lesions, especially in AIDS
patients. To study the expression of JCV in glial cells, the role of both repeat region TGAGCTCA sequences, which are
homologous to the classical TGAGCTCA cAMP response element (CRE), was examined. The effect of the CRE on expression
of the JCV early promoter (JCVE) in response to cAMP was studied with undifferentiated, glial and muscle P19 embryonal
carcinoma cells. The results showed a threefold increase in response to cAMP only in the glial cells in which JCV is
efficiently expressed. The direct in vivo role of the JCV CRE was confirmed by site-directed mutagenesis. Additionally, a
CRE oligonucleotide was induced by cAMP in vivo, and in in vitro transcription assays with glial cell extracts. The early
promoter of human BK virus containing nonhomologous CRE sequences was previously shown not to be glial cell-specific
and failed to respond to cAMP in glial P19 cells in this study. Mobility shift assays showed the cAMP-induced in vitro
interaction of glial cell protein(s) with the CRE oligonucleotide. Southwestern blot and uv crosslinking experiments identified
an approximately 43-kDa protein interacting with the JCV CRE oligonucleotide. The results indicate that the in vivo expression
of JCVE is specifically increased in response to cAMP only in glial cells and JCV CRE in vitro protein complexes are only
detected in response to cAMP for glial cell extracts. q 1996 Academic Press, Inc.
INTRODUCTION Major et al., 1992; Henson, 1994). Site-directed mutagene-
sis indicated a functional role for NF-1 binding sequences
The human JC polyomavirus (JCV) is a neurotropic virus in the 98-bp repeats for the restricted cell specificity of JCV
and has been strongly implicated as the principle cause (Kumar et al., 1993).
of the demyelinating disease, progressive multifocal leu- Another JCV sequence, which has close homology to the
koencephalopathy (Brooks and Walker, 1984; Padgett et consensus cAMP response element (CRE), was previously
al., 1977). This serious demyelinating disease occurs in identified in each 98-bp repeat of the regulatory region
immunocompromised individuals. Importantly, JCV-positive (Amemiya et al., 1992). A significant number of neurotropic
lesions caused by this disease have recently been ob- genes are among the viral and cellular genes that are
served much more frequently because of the epidemic of regulated by cAMP and contain a CRE in their noncoding
the AIDS virus and the brain pathologies of both viruses regions (Borrelli et al., 1992; Habener, 1990; Montminy et
may be enhanced by cooperative gene expression (Tada al., 1990). Analysis of these sequences identified TGA-
et al., 1990). JCV exhibits strict specificity for glial cells and CGTCA as the CRE consensus sequence (Montminy et al.,
this restricted cell specificity has been attributed to the role 1990). The CRE has not been characterized for its functional
of regulation of viral gene transcription. The JCV regulatory significance. We studied here the JCV CRE-homologous
region, which is important for specificity for glial cells, has sequence in the viral regulatory region, to learn the contri-
been narrowed to the two 98-bp tandem repeats (Feigen- bution of cAMP to the brain-specific biological function of
baum et al., 1987; Kenney et al., 1984; Nakshatri et al., 1990; JCV gene expression. JCVE expression was increased sub-
Tada et al., 1989). Previous studies indicated that the JCV stantially by cAMP and only in P19 mouse embryonal carci-
regulatory region consists of binding sites for a number of noma glial cells. An oligonucleotide of this CRE was in-
transcription factors, including NF-1, AP-1, SP-1, NF-kB, Tst- duced for expression in vivo in assays with glial cells and
1, and GF-1, some of which contribute to the glial cell- in vitro with glial cell extracts. The JCV CRE oligonucleotide
specificity of this virus (reviewed in Frisque and White, 1992; also could detect the specific binding of a 43-kDa protein
only in response to cAMP.
1 Present address: Banting and Best Department of Medical Re- MATERIALS AND METHODS
search, University of Toronto, Ontario, Canada M5G 1L6.
2 Mary Pater passed away on November 2, 1994 and this paper is Plasmids and site-directed mutagenesis
dedicated in her memory.
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(RII) containing a single wild-type 98-bp repeat se- Ribonuclease protection assay
quence, were described previously (Kumar et al., 1993).
P19 glial cells in 100-mm plates were transfected withThe pBKEcat plasmid, with the intact early BKV regulatory 10 mg pJCEcat and incubated 24 hr with or without 100region, was also described previously (Nakshatri et al.,
mM forskolin. Total cellular RNA was prepared 48 hr after1991). Site-directed mutagenesis of the JCVE CRE in transfection and 10 mg were assayed, as described pre-pJCVEcat and pRIIJCEcat, to give pmJCEcatI.II (I.II) and
viously (Belaguli et al., 1992). RNA CAT probe for expres-pmRIIEcat (mRII), respectively, used previously de-
sion of JCV and internal control pRSVcat (pRSV-Cat) wasscribed methods (Kumar et al., 1993). The four JCV plas-
from the HindIII to EcoRI (nt 5018–4768) fragment ofmids are diagrammed in Fig. 1. An AGCATGAGCTCA JCV
pSV2cat. RNA probe for expression of b-galactosidaseCRE oligonucleotide was inserted into the enhancerless
(b-Gal) internal control was from the EcoRI to AvaI (ntpBLcat2, to give pJCCREcat expression vector. All plas-
3286–3063) fragment of b-Gal from pCH110 (Pharmacia,mid constructs were confirmed by sequencing.
Piscataway, NJ).
Cell culture and transfection Whole cell extract preparation and mobility shift
assay
P19 undifferentiated (UD) mouse embryonal carci-
Whole cell extract preparation from P19 glial cells andnoma cells were differentiated into a mixture of glial cells
forskolin-treated P19 glial cells was as described (Tassetand neurons by retinoic acid (RA) treatment and were
et al., 1990). Mobility shift assays were as describeddifferentiated by dimethylsulfoxide treatment to form
previously (Kumar et al., 1993).skeletal and cardiac differentiated muscle (DM) cells, as
described previously (Kumar et al., 1993; Rudnicki and
Southwestern blot analysisMcBurney, 1987). Cells were seeded, incubated for 8 hr,
transfected with 5 mg test plasmid and 15 mg carrier JCV CRE oligonucleotide probe and 50 mg of glial cell
pUC19, incubated for 24 hr, and then another 24 hr with protein in extracts were used, as described (Vinson et
and without 10 mM dibutyryl cAMP or 100 mM forskolin al., 1988).
(Sigma Chemical Co., St. Louis, MO), the amounts used
by other investigators. A 48-fold range of time periods UV crosslinking assay
was used in preliminary experiments to determine the
JCV CRE 12-mer oligonucleotide was nick-translatedoptimum 24-hr induction time of cAMP and forskolin.
in the presence of [32P]dCTP and 5-bromodeoxyuridine,Also, the same volume of DMSO that was used to dis-
using the kit and instructions (GIBCO-BRL, Bethesda,solve forskolin had no effect (data not shown).
MD) with appropriate concentrations of reaction ingredi-
ents. Poly(dI.dC) was increased to 7.5 mg and other meth-
Chloramphenicol acetyltransferase (CAT) assay ods were as described (Chodosh et al., 1986).
CAT assay with the appropriately diluted extracts for In vitro transcription assay
expression of JCV in P19 cells was as described pre-
viously (Kumar et al., 1993). Values were normalized with In vitro transcription assays were as described earlier
(Kumar et al., 1993). Whole cell extracts from forskolin-b-galactosidase (b-Gal) assays of the RSV-promoter-b-
galactosidase plasmid. treated and untreated P19 glial cells were prepared, as
FIG. 1. Wild-type and mutated CRE motifs of JCVE sequences in expression plasmids. Top, diagram of sequences present in CAT plasmids. Early
and late sides are indicated. Insertion sites are numbered and arrowed for whole JCVE (nt 5112–270) and single 98-bp repeat (nt 66–164) fragments.
TATA boxes and CRE motifs are indicated and delineated by thick lines. Nucleotide positions are given below and above the lines. Open boxes
indicate the 98-bp repeats. Bottom, list of mutated plasmids and sequences for the nt 56 CRE II and nt 154 CRE I motifs. Mutated CRE nucleotides
are indicated by lower case letters and wild-type CRE nucleotides are indicated by capital letters.
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FIG. 2. Effect of cAMP on functional expression from JCVE whole enhancer and single 98-bp repeat and BKVE whole enhancer in differentiating
P19 cells. Results shown are averages and standard deviations. (A) JCVE assays were with undifferentiated (UD), differentiated muscle (DM), and
glial retinoic acid (RA) differentiated P19 cells for untreated control cells, forskolin-treated (FSK) cells, and dibutyryl cAMP-treated (cAMP) cells.
Expression plasmids used are pRIIJCEcat repeat (RII) and pJCEcat (WT) whole constructs (Fig. 1). Three experiments with different cell preparations
were performed. (B) The pBKEcat (BKE) whole enhancer containing a CRE was assayed in glial RA cells as a control. Two experiments were
performed.
described (Tasset et al., 1990). NcoI-digested pBLcat2 results support the CAT assay results and indicate that
the effect of cAMP on the expression of JCVE is at theand pJCCREcat were used as templates to assay the
576-nt CAT transcript. level of RNA in glial cells.
RESULTS Role of JCV CRE in response to cAMP
Role of cAMP in glial cell-specific expression of JCV Next, the direct involvement of the JCV CRE in the re-
sponse to cAMP was tested by specific mutations in CRETo examine whether cAMP has a role in JCV expres-
sion in glial cells, the WT pJCEcat JCVE and pRIIJCEcat
(RII) single repeat expression plasmids were transfected
into undifferentiated and into differentiated muscle and
glial P19 mouse cells. The cells were then untreated or
treated with dibutyryl cAMP or forskolin (FSK) to increase
and/or induce the intracellular cAMP levels (Fig. 2A). Un-
differentiated, UD, and DMSO-differentiated muscle, DM,
P19 cells gave negligible and low, respectively, expres-
sion in CAT assays from these plasmids in the absence
and presence of cAMP. In glial cells differentiated by
RA, both plasmids were functional. Addition of cAMP
enhanced the expression from pJCVEcat (WT) and
pRIIJCEcat (RII) by two- to threefold. Forskolin treatment
increased expression of these plasmids to similar levels
(Fig. 2A). As a control for the cAMP response of a CRE
of a heterologous promoter, the early promoter of the
related human polyomavirus, BKV, was examined. Unlike
JCV, the BKV promoter was not specific to P19 glial cells
in previous studies (Nakshatri et al., 1991). Furthermore,
there was no significant response of BKV to cAMP or FIG. 3. Effect of cAMP on RNA expression from JCVE in glial cells.
The RNase protection assay lanes are: CAT/b-Gal, RNA from glialforskolin in glial P19 cells (Fig. 2B). Thus, the results
cells cotransfected with pRSVcat, and pRSV-b-galactosidase as doublerevealed a role of cAMP and the unique JCV promoter
positive expression controls; E-FSK and E, RNA from forskolin-treatedand 98-bp repeat containing the CRE in enhancing the
and forskolin-untreated glial cells, respectively, cotransfected with
high basal viral expression level in glial cells. pJCVEcat and pRSV-b-galactosidase; tRNA, E. coli tRNA negative con-
The role of cAMP for expression of JCVE at the RNA trol; P, untreated probes for b-Gal (star on the right) and CAT (arrow-
head on the right). CAT and b-Gal protected RNase T1 RNA fragmentslevel was examined using RNase protection assays of
are indicated on the left. Molecular marker (M) sizes are indicated inRNA from forskolin-treated and untreated control P19
bases on the right. A higher molecular weight band was also detected,glial cells transfected with pJCEcat (WT). The expression
but was also present in the tRNA negative control lane. Band intensities
of JCVE was quantified relative to the co-expressed b- for pJCVEcat CAT product in appropriately exposed autoradiograms
Gal (Fig. 3). The glial cells treated with forskolin had 2.9- were quantified by densitometry and standardized with the coex-
pressed b-Gal.fold more CAT transcripts than untreated cells. These
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FIG. 4. Effect of mutation of JCV CRE motifs on functional expression
in glial cells. Assays and labels are as described in the legends of Fig.
FIG. 5. Induced expression by cAMP in glial cells of JCV CRE oligonu-1 and 2. The results are averages of two experiments with whole
cleotide. The pBLcat2 control and pJCCREcat oligonucleotide expres-enhancer pJCEcat wild-type (WT) and mutated pmJCEcat (mI.II) plas-
sion vectors are indicated. The three values for pBLcat2 were sub-mids and single 98-bp nonmutated pRIIJCCREcat (RII) and mutated
tracted from the respective pJCCREcat assay values to calculate thepmRIIJCEcat (mRII) plasmids.
fold induction. The 41 and 81 indicate in vivo competition by cotrans-
fection with pJCCREcat and four- and eightfold molar excess JCV CRE
oligonucleotide inserted into pUC19. The control assays for thesewith site-directed mutagenesis. The mutated enhancer
assays were the assays (Control) for pJCCREcat. Other conditions andfragments were inserted into the same expression vector
labels are as described in the legend of Fig. 4.as wild-type plasmids (Fig. 1). Plasmids were then tested
for their functional activity in response to cAMP in P19 glial
cells (Fig. 4). Similar activities were found in the control additional nonCRE JCVE motifs in the whole viral en-
untreated glial cells of the corresponding wild-type and hancer constructs (Figs. 2–4). The in vivo induction of
mutated constructs, both for JCVE (WT and I.II) and for JCCREcat was substantially reduced by adding 4-fold
single 98-bp repeat (RII and mRII). The wild-type whole excess molar ratio of a cotransfected competitor CRE
enhancer pJCEcat (WT) and single 98-bp repeat pRIIJCE- oligonucleotide and was not more than pBLcat2 levels
cat (RII) constructs were again responsive to cAMP and for 8-fold excess competition (Fig. 5).
to forskolin in glial cells, resulting in two- to threefold The same heterologous construct was used to exam-
higher expression. However, mutations of both CREs in ine whether specifically the CRE in JCV that showed the
whole JCVE (I.II) and the single CRE in one 98-bp repeat effect of cAMP in in vivo experiments, also shows a re-
(mRII) blocked the response of JCVE to cAMP and to for- sponse in in vitro transcription assays (Fig. 6). The
skolin, indicating that the integrity of the JCV CREs is pBLcat2 vector was inactive for extract from glial cells
essential for induction by cAMP of JCVE (Fig. 4).
Induction by cAMP of expression from JCV CRE
oligonucleotide in a heterologous promoter
We next examined the sufficiency of the JCVE CRE
sequence as an enhancer motif responding to cAMP
from the heterologous thymidine kinase promoter. This
heterologous promoter vector system uses the conve-
niently designed pBLcat2 enhancerless plasmid for ex-
amining the function of enhancer sequences. Assays for
the pBLcat2 vector indicated a background activity and
little effect of cAMP (Fig. 5). Thus, to examine the effect
of only the JCV CRE from this nonresponsive promoter, FIG. 6. Role of cAMP in in vitro transcription from JCV CRE oligonucle-
otide in glial cell extract. The pBLcat2 and pJCCREcat DNA templatesan oligonucleotide was inserted into pBLcat2 to produce
used are indicated. Competitor was 250-fold excess CRE oligonucleo-pJCCREcat and the activity was subtracted by that for
tide; other lanes are: a-a, a-amanitin; FSK, forskolin induction of cAMP;pBLcat2. Glial cell expression from the CRE oligonucleo-
RA, uninduced glial cells. CAT, Tr, and control b-Gal RNA (RSV-b-Gal)
tide in pJCCREcat was induced 12-fold by cAMP (Fig. 5). transcripts are indicated. Band intensities were calculated as described
This increase in activity was greater than the results for in the legend of Fig. 3. Due to a loading error the second lane from
the right represents less sample.JCVE , probably due to the high basal activities from the
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induced for cAMP (FSK). Activity was also not detected
from pJCCREcat CRE oligonucleotide with extract from
RA uninduced cells. However, transcriptional activity was
observed for glial cells following induction of cAMP for
assays with pJCCREcat (FSK). This activity was com-
pletely competed by 250-fold excess CRE oligonucleo-
tide (Fig. 6). The activity was due to RNA polymerase II,
as shown with a-amanitin (a-a). Overall, the expression
assay results evidenced the enhanced glial cell function
of specifically the CRE in JCVE in response to cAMP.
Interaction of JCVE CRE with glial cell protein(s)
induced by cAMP FIG. 8. Size of glial cell protein induced by cAMP, as determined
by Southwestern blot analysis. Numbers on the right indicate protein
markers in kDa. Arrow indicates the 43-kDa protein interacting withThe in vivo competition by the CRE in cAMP-induced
the CRE oligonucleotide probe. The bands in the duplicate lanes for theP19 glial cells suggested the interaction of a factor(s)
untreated (RA) and forskolin-treated (FSK) cells are from two separatewith the JCV CRE sequence, which often can be detected
experiments. The experiments were repeated, consistent, and
for transcription factors by in vitro binding assays. There- analyzed, as described in the legend of Fig. 7.
fore, mobility shift assays were used with a JCV CRE
oligonucleotide probe (Fig. 7). The extract from untreated
by specific (S) CRE oligonucleotide. A functional NF-1,(0FSK) glial cells gave no apparent CRE binding (B).
CRE-nonspecific (NS) oligonucleotide (Kumar et al., 1993)However, there was definite binding, as single complex,
had no effect on binding to the CRE (Fig. 7).for two different preparations of cAMP-induced (/FSK)
To study the number and size of polypeptide(s) directlyglial cell extracts. This complex, with extract used for the
interacting with the JCV CRE, Southwestern blot and uvB lane on the right, was not detectable with competition
crosslinking assays were used. Southwestern blot analy-
sis revealed a 43-kDa protein from cAMP-induced P19
glial cells specifically interacting with the CRE oligonu-
cleotide. A control probe was a nonCRE sequence, the
functional nt 7474 HPV 16 GRE (Mittal et al., 1993), which
was not bound by the 43-kDa protein (data not shown).
No interaction of protein(s) from untreated P19 glial cells
was detected (Fig. 8). Ultraviolet crosslinking experi-
ments were also done, since they allow binding to multi-
ple subunit proteins and protein–protein complexes,
which may be required but are disassociated during de-
naturing gel electrophoresis for Southwestern blots. The
result convincingly confirmed the Southwestern results.
Again, no binding was detected for untreated glial cells.
Two proteins of approximately 150- and 43-kDa from for-
skolin-treated cells were apparent with the JCV CRE oli-
gonucleotide (Fig. 9). Further, in the presence of two
nonspecific (NS1 and NS2) oligonucleotides for the func-
tional JCV NF-1 II and NF-1 I sequences, respectively
(Nakshatri et al., 1990; Kumar et al., 1993), the binding
of the 43-kDa protein was substantial and the minor re-
duction may have been due to a minor contribution of
nonspecific interaction. However, the 150-kDa proteinFIG. 7. Induction by cAMP of JCV CRE oligonucleotide binding in
was similarly reduced, whereas the specific CRE com-mobility shift assays with glial cell extracts. The broad arrow on the
petitor eliminated the binding only of the 43-kDa proteinleft indicates the specific low mobility DNA–protein complex. Lanes:
0FSK, forskolin-untreated P19 glial cell extract;/FSK, forskolin-treated (Fig. 9). Taken together, the in vitro binding assays sug-
cell extract; F, free CRE probe (arrow) in the absence of extract; B, gest that an approximately 43-kDa protein from P19 glial
binding without competitor. The two B lanes are for two different ex- cells interacts with the JCV CRE in a sequence-specific
tracts from two independent experiments; S, specific competition by
manner in response to cAMP.250-fold excess homologous competitor CRE oligonucleotide; NS, non-
specific competition by 250-fold excess JCV NF-1 II oligonucleotide DISCUSSION
(Kumar et al., 1993). The experiments were repeated three times and
Brain-specific gene expression is important for the nor-analyzed, and the results were qualitatively and quantitatively consis-
tent for different exposure times for the autoradiograms. mal development and differentiated function (Kahle et al.,
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apparently a unique protein. The highly restricted brain
cell specificity of most strains of JCV suggests that only
glial cell-specific forms of factors, such as CREB and the
many other transcription factors important for glial cell
specificity, functionally interact with the neurotropic JCV
enhancer.
One of the mechanisms for the specificity of the JCV
CRE could involve glial cell-specific modification of
CREB. For example, the functional interaction of CREB
with JCV CRE may require that CREB be phosphorylated
by protein kinase A (PKA). This is supported by the re-
quirement for induction of the JCV CRE specifically in
glial cells after forskolin treatment which activates phos-
FIG. 9. Size of protein induced by cAMP, as determined by uv cross-
phorylation of CREB by PKA (Yamamoto et al., 1988). Onlylinking assays. The two B lanes are for two different extracts from
phosphorylated CREB can bind the CREB binding proteintwo independent experiments. Lanes for assays with 500-fold excess
oligonucleotide competitors: S, specific CRE; NS1, nonspecific NF-1 II (CBP), which has been proposed to enhance the cAMP
(Kumar et al., 1993); NS2, nonspecific NF-1 I (Kumar et al., 1993). Other response of the constitutively expressed CREB (Chrivia
labels, reproducibility, and analyses were as described for Figs. 7 et al., 1993). JCV CRE may require a specific glial CBP.
and 8.
Alternatively, the PKA of glial cells may be specific, since
in different tissues there are different isoforms of PKA
(Auwerx and Sassone-Corsi, 1991). One of these iso-1994; Stipp et al., 1994). One mechanism for the regula-
tion of expression of many critical brain gene products forms may specifically phosphorylate CREB, depending
on the cell type. Moreover, the phosphorylation of CREBand functions is through the cAMP second messenger
(Montminy et al., 1990; Cooper et al., 1995). Tyrosine is also regulated by kinases other than PKA (Habener,
1990). Therefore, these different kinases could be im-hydroxylase is among those cellular genes regulated di-
rectly through CREs; this enzyme is specifically found in portant for the response to the particular physiological
status of different cells and the regulation of the specificbrain cells (Stone and John, 1991). The CRE binding pro-
tein (CREB) has been found to be important for the com- genes (Roesler et al., 1993), such as those of JCV that
are specifically expressed in glial cells.plex function of memory (Frank and Greenberg, 1994; Yin
et al., 1995). Further, JCV pathology is specific to the glial A 12-fold induction in response to cAMP was observed
for the JCV CRE oligonucleotide from a heterologous pro-type of brain cells. JCV causes progressive multifocal
leucoencephalopathy in glial brain cells. The CRE of JCV moter. This increase for expression of the CRE oligonu-
cleotide was more than the 2- to 3-fold increase for JCVEwas found to interact with a factor related to the c-jun
proto-oncogene (Amemiya et al., 1992). A possible role complete enhancer and 98-bp enhancer fragments, most
likely due to the contribution of other factors that increasewas also suggested for another motif which overlaps the
CRE and has been termed the SacI motif (Tamura et al., the basal expression for both fragments containing addi-
tional important motifs. The clear 12-fold response from1990). This study demonstrated in vitro interactions with
this CRE and the important contribution of glial cell-en- the CRE oligonucleotide indicates that the regulation of
expression from CRE does not require the other JCV en-hanced functions of JCV CRE for JCV expression.
We found that binding activity of JCV CRE oligonucleo- hancer motifs. Additionally, the other motifs and proteins
were not required for in vitro binding, since specific bind-tide was specifically detectable with three types of
assays of P19 glial cell extracts, and only after cAMP ing of the 43-kDa protein with the JCV CRE oligonucleo-
tide was shown by Southwestern blots to be independenttreatment of the cells. CREB is ubiquitously expressed
in transgenic mice (Struthers et al., 1991). However, there of association with other proteins. For JCV transcription
in glial cells, instead of adjacently binding transcriptionare several proteins belonging to the CREB family bind-
ing to CRE and related sequences bind factors that mod- factors such as NF-1 modulating CREB function, the bind-
ing to CREB of other proteins such as CBP (Chrivia etulate CREBs (Foulkes et al., 1991). Other transcription
factors such as NF-1 are also ubiquitous, but function al., 1993) may modulate expression without directly inter-
acting with JCVE .for JCVE is specific to P19 glial cells (Kumar et al., 1993).
The closely homologous BK virus (BKV) has a similar CREBs are a family of proteins ranging in size from 39
to 120 kDa. Among these is a 43-kDa species from ratnatural history to JCV, contains a partially homologous
CRE, and responds to cAMP (Cassill et al., 1989; Moens brain cells binding to the CRE of the somatostatin gene
which is expressed in specific brain tissues (Montminyet al., 1990). However, BKV is not specific for expression
in P19 glial cells (Nakshatri et al., 1991). Moreover, this and Bilezikjian, 1987). The rat F9 RA-treated cells were
also inducible for expression by cAMP through an inter-report showed that BKV did not respond to cAMP in P19
glial cells (Fig. 2B). Therefore, the CREB of glial cells acting 43-kDa protein for this neurotropic gene (Rickles
et al., 1989). Mutations described here abrogated se-that functionally recognizes the JCV CRE in JCVE was
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peptide possesses the binding and transcription activities of thequences completely. Whether the mouse 43-kDa protein
adenovirus major late transcription factor. Mol. Cell. Biol. 6, 4723–of P19 glial cells binding to the distinct JCVE CRE is 4733.
analogous could be investigated by the use of CRE se- Chrivia, J. C., Kwok, R. P. S., Lamb, N., Haglwara, M., Montminy, M. R.,
quences specific to members of the family of distinct and Goodman, R. H. (1993). Phosphorylated CREB binds specifically
CREBs. In addition, further analysis of wild-type and mu- to the nuclear protein CBP. Nature 365, 855–859.
Cooper, D. M. F., Mons, N., and Karpen, J. W. (1995). Adenylyl cyclasestated CRE, using in vitro transcription and various binding
and the interaction between calcium and cAMP signalling. Natureassays, is of interest.
374, 421–424.Regulation of JCV expression appears to be complex.
Feigenbaum, L., Khalili, K., Major, E., and Khoury, G. (1987). Regulation
A motif which is homologous to the NF-kB motif of HIV- of the host range of human papovavirus JCV. Proc. Natl. Acad. Sci.
1 has been identified outside the core regulatory region USA 84, 3695–3698.
Foulkes, N. S., Borelli, E., and Sassone-Corsi, P. (1991). CREM gene:of JCV. This motif stimulated expression of the JCV late
Use of alternative DNA binding domains generates multiple antago-promoter in glial cells and interacted with nuclear pro-
nists of cAMP-induced expression. Cell 64, 739–749.teins which are phorbol ester inducible or unique consti-
Frank, D. A., and Greenberg, M. E. (1994). CREB: A mediator of long-tutive proteins in glial cells (Ranganathan and Khalili, term memory from mollusks to mammals. Cell 79, 5–8.
1993). Therefore, a significant contribution to the glial Frisque, R. J., and White, F. A. (1992). The molecular biology of JC virus,
cell-enhanced expression of JCV appears to be regulated causative agent of progressive multifocal leukoencephalopathy. In
‘‘Molecular Neurovirology’’ (R. P. Roos, Ed.), pp. 25–158. Humanaby CREB and NF-kB inducible transcription factors and
Press, Totowa, NJ.different NF-1 and NF-kB constitutive transcription fac-
Habener, J. F. (1990). Cyclic AMP response element binding proteins:tors. Importantly, the mechanisms for induction of NF-
A cornucopia of transcription factors. Mol. Endocrinol. 4, 1087–1094.
kB are through different signal transduction pathways, Henson, J. W. (1994). Regulation of the glial-specific JC virus early
through phosphorylation with PKA and PKC, whereas promoter by the transcription factor Spl. J. Biol. Chem. 269, 1046–
1050.CREB is not activated by PKC (Baeuerle and Baltimore,
Kahle, P., Mangold, M., Kuwahara, T., Schubenel, R., and Hertel, C.1988). The combination of transcription factors that inter-
(1994). Protein kinase inhibitor H-7 differentially affects early andact with the unique motifs and are regulated by different
delayed nerve growth factor responses in PC12 cells. J. Neurochem.environmental signals may maintain a more continuous
62, 479–488.
and flexible in vivo JCV transcriptional response than Kenney, S., Natarajan, V., Strike, D., Khoury, G., and Salzman, N. P.
individual motifs and factors. The identification and char- (1984). JC virus enhancer-promoter active in human brain cells. Sci-
ence 226, 1337–1339.acterization of such motifs and their binding factors
Kumar, K. U., Pater, A., and Pater, M. M. (1993). Human JC virus perfectshould further our understanding of the regulation of JCV
palindromic nuclear factor 1-binding sequences important for glialgenes as well as other brain-specific genes.
cell-specific expression in differentiating embryonal carcinoma cells.
J. Virol. 67, 572–576.
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